A share price of Roivant Sciences Ltd [ROIV] is currently trading at $10.58, down -0.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ROIV shares have gain 4.03% over the last week, with a monthly amount drifted -2.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Roivant Sciences Ltd [NASDAQ: ROIV] stock has seen the most recent analyst activity on February 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $17. Previously, Piper Sandler started tracking the stock with Overweight rating on January 05, 2024, and set its price target to $20. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $14 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 17, 2023. BofA Securities initiated its recommendation with a Neutral and recommended $10.50 as its price target on June 08, 2023. JP Morgan started tracking with a Overweight rating for this stock on October 27, 2022, and assigned it a price target of $7. In a note dated May 23, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Roivant Sciences Ltd experienced fluctuations in its stock price throughout the past year between $9.76 and $13.06. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Roivant Sciences Ltd [NASDAQ: ROIV] shares were valued at $10.58 at the most recent close of the market. An investor can expect a potential return of 46.5% based on the average ROIV price forecast.
Analyzing the ROIV fundamentals
Trailing Twelve Months sales for Roivant Sciences Ltd [NASDAQ:ROIV] were 97.56M which represents -75.72% decline. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -10.27%, Pretax Profit Margin comes in at -5.95%, and Net Profit Margin reading is -1.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.43 points at the first support level, and at 10.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.77, and for the 2nd resistance point, it is at 10.96.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Roivant Sciences Ltd [NASDAQ:ROIV] is 37.91. As well, the Quick Ratio is 37.91, while the Cash Ratio is 14.07. Considering the valuation of this stock, the price to sales ratio is 77.38, the price to book ratio is 1.47.
Transactions by insiders
Recent insider trading involved Venker Eric, President & COO, that happened on Feb 20 ’25 when 100000.0 shares were sold. Officer, Venker Eric completed a deal on Feb 20 ’25 to buy 100000.0 shares. Meanwhile, Chief Accounting Officer Kumar Rakhi sold 0.23 million shares on Feb 13 ’25.
